Seres therapeutics presents late-breaking phase 3 data on investigational microbiome therapeutic ser-109 in recurrent c. difficile infection at american college of gastroenterology 2021 annual scientific meeting

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced late-breaking data from its phase 3 ecospor iii study evaluating ser-109, an investigational oral microbiome therapeutic for recurrent c. difficile infection (rcdi). new data from an exploratory analysis demonstrate ser-109 reduced the risk of rcdi compared to placebo in patients with risk factors for recurrence, including those taking acid-reducing medications
MCRB Ratings Summary
MCRB Quant Ranking